NCT00679172 - Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults | Biotech Hunter

Enrollment

187

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Typhoid

Interventions

BIOLOGICAL

Dose of 5.0 x 10^9 CFU (Cohort 1)

S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration

BIOLOGICAL

Dose of 7.5 x 10^9 CFU (Cohort 2)

S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration

BIOLOGICAL

Dose of 1.1 x 10^10 CFU (Cohort 3)

S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration

BIOLOGICAL

Dose of of 1.7 x 10^10 CFU (Cohort 4)

S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration

OTHER

Placebo (Cohorts 1-4 pooled)

Excipients only, single dose, oral administration

Trial Locations (3)

John Hopkins Bloomberg School of Public Health, Baltimore

Miami Research Associates, South Miami

Unit of Infectious Diseases, University of Vermont College of Medicine, Burlington